ARTICANZ - Beta (ver 0.91)

Annotated Registry of Trials in Cancer, Australia and New Zealand Ed. - Results - location/NSW/2444-Port-Macquarie-Mid-North-Coast-Cancer-Institute-Port-Macquarie-Base-Hospital

Search results

17 trial(s) found.
NCT06960577
NA
NA
NCT06892522
NCT06846671
NCT06764485
NCT06492616
NCT06417814
NCT06170788
3350 - Ballarat - Grampians Health Service's Ballarat Base Hospital (COMPLETED)
NCT06117774
NCT05911295
NCT05794906
2010 - Darlinghurst - St Vincent's Hospital Sydney - The Kinghorn Cancer Centre (WITHDRAWN)2109 - North Ryde - Macquarie University Hospital (WITHDRAWN)2145 - Westmead - The Crown Princess Mary Cancer Centre - Westmead Hospital (WITHDRAWN)2148 - Blacktown - Blacktown Hospital, Blacktown Cancer and Haematology Centre (WITHDRAWN)2298 - Waratah - Calvary Mater Newcastle Medical Oncology (WITHDRAWN)2444 - Port Macquarie - Mid North Coast Cancer Institute-Port Macquarie Base Hospital (WITHDRAWN)
3000 - Melbourne - Peter MacCallum Cancer Centre (WITHDRAWN)3144 - Malvern - Cabrini Health, Cabrini Cancer Care Centre (WITHDRAWN)
4215 - Southport - Tasman Oncology (WITHDRAWN)4655 - Urraween - Cancer Care Service, Hervey Bay Hospital (WITHDRAWN)4670 - Bundaberg - Bundaberg Hospital, Genesis Cancer Care (WITHDRAWN)
NCT05552976
NCT04928846
NCT04613596
3168 - Clayton - Monash Medical Centre (WITHDRAWN)
NCT04332822
NCT03486873
4101 - South Brisbane - Mater Hospital Brisbane / ICON Cancer Centre (COMPLETED)
ACTRN12619000566134
ACTRN12622000973718
Filters
PD-1/PD-L1
29%
PD-1
24%
proteasome
12%
CD20
12%
AR
12%
androgen axis
12%
Trop2
12%
KRAS
12%
KRAS G12C
12%
VEGF
12%
PD-L1
6%
BCMA
6%
CD38
6%
cereblon
6%
BTK
6%
Bcl2
6%
PI3K delta
6%
CYP17A1
6%
ER
6%
oestrogen axis
6%
EGFR
6%
DLL3
6%
ERBB2
6%
MET
6%
CD79b
6%
LAG3
6%
PARP
6%
PDE4
6%
HRAS G12C
6%
NRAS G12C
6%
NA 




















 






























	
		
	

    

        

			ARTICANZ (Annotated Registry of Trials in Cancer, Australia/NZ Edition; ARTificial Intelligence-enhanced CANcer trial information database) provides information about cancer drug trials in Australia and New Zealand as a free, open-information platform. Please note the following:

			
    
			
  • Data Accuracy: While ARTICANZ strives to maintain accurate and up-to-date information through regular weekly updates and specialist review, we cannot guarantee the complete accuracy, reliability, or timeliness of all data. Information may change between updates.
    • 
			
			
  • Not Medical Advice: The information provided by ARTICANZ is for informational purposes only and should not be considered medical advice. All clinical decisions should be made in consultation with qualified healthcare professionals.
    • 
			
			
  • No Warranty: ARTICANZ is provided "as is" without any warranties, expressed or implied. We disclaim all liability for any damages arising from the use of or inability to use this platform.
    • 
			
			
  • External Links: ARTICANZ may contain links to external websites. We are not responsible for the content or privacy practices of these sites.
    • 
			
			


			By using ARTICANZ, you acknowledge that you have read and understood this disclaimer.
			
		

        

            
The ARTICANZ platform and its contents are made available under the Creative Commons Attribution 4.0 International License (CC BY 4.0).

            
            
Users are free to:

            
    
                
  • Share — copy and redistribute the data in any medium or format
    • 
                
  • Adapt — remix, transform, and build upon the data
    • 
                
  • Use the data for any purpose, including commercial use
    • 
            

            
            
Under the following terms:

            
    
                
  • Attribution — You must give appropriate credit to ARTICANZ, provide a link to the license, and indicate if changes were made
    • 
                
  • No additional restrictions — You may not apply legal terms or technological measures that legally restrict others from doing anything the license permits
    • 
            

            
            
Platform developed and currently maintained by Dr. Frank Lin and the ARTICANZ team.